Literature DB >> 16094421

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.

B Bruno1, L Giaccone, M Rotta, K Anderson, M Boccadoro.   

Abstract

Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its pathogenesis have identified signaling pathways that have become potential therapeutic targets. It has clearly been established that intracellular regulatory proteins and interactions between malignant plasma cells and the bone marrow microenvironment play an important role in their survival and drug resistance. Several new agents associated with molecular targets are currently being investigated to design new treatment strategies aimed at prolonging survival and improving quality of life. This review illustrates their mechanisms of action and the possible future clinical applications.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16094421     DOI： 10.1038/sj.leu.2403905

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  15 in total

1.  Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

Authors:  M Ladetto; S Ferrero; D Drandi; M Festuccia; F Patriarca; N Mordini; S Cena; R Benedetto; G Guarona; F Ferrando; L Brunello; P Ghione; V Boccasavia; R Fanin; P Omedè; L Giaccone; A Palumbo; R Passera; M Boccadoro; B Bruno
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

2.  The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Authors:  Camille Bono; Lionel Karlin; Stephanie Harel; Enguerran Mouly; Sylvaine Labaume; Lionel Galicier; Sébastien Apcher; Hélène Sauvageon; Jean-Paul Fermand; Jean-Christophe Bories; Bertrand Arnulf
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

3.  Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.

Authors:  L Giaccone; L Brunello; M Festuccia; M Gilestro; E Maffini; F Ferrando; E Talamo; R Passera; M Boccadoro; P Omedè; B Bruno
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

5.  HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.

Authors:  Choon-Kee Lee; Shuiliang Wang; Xiaoping Huang; John Ryder; Bolin Liu
Journal:  Cancer Lett       Date:  2010-05-05       Impact factor: 8.679

6.  Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Authors:  Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharsky; Nicole Chan; Hasan Uludağ
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

7.  The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

Authors:  Shuhong Zhang; Attaya Suvannasankha; Colin D Crean; Valerie L White; Ching-Shih Chen; Sherif S Farag
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

8.  The role of microenvironment in tumor angiogenesis.

Authors:  Domenico Ribatti; Angelo Vacca
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

9.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

10.  Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Authors:  Frits van Rhee; Susann M Szmania; Myles Dillon; Anne M van Abbema; Xin Li; Mary K Stone; Tarun K Garg; JuMei Shi; Amberly M Moreno-Bost; Rui Yun; Balaji Balasa; Bishwa Ganguly; Debra Chao; Audie G Rice; Fenghuang Zhan; John D Shaughnessy; Bart Barlogie; Shmuel Yaccoby; Daniel E H Afar
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.